3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
3
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Melanoma
7
Colorectal Neoplasms
7
Carcinoma, Renal Cell
7
Neoplasms
6
Lymphoma, Non-Hodgkin
6
Carcinoma, Non-Small-Cell Lung
6
Uterine Cervical Neoplasms
4
Prostatic Neoplasms
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Lymphoma
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Carcinoma, Merkel Cell
4
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Head and Neck Neoplasms
3
Carcinoma, Transitional Cell
3
Small Cell Lung Carcinoma
2
Skin Neoplasms
2
Lymphoma, Follicular
2
Lymphoma, B-Cell
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Hematologic Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Interventions
Rituximab
23
Lenalidomide
11
Cyclophosphamide
10
zanubrutinib
9
Bendamustine Hydrochloride
8
venetoclax
6
ibrutinib
6
fludarabine
6
parsaclisib
5
idelalisib
5
ublituximab
4
obinutuzumab
4
aflibercept
4
Prednisone
4
pirtobrutinib
3
Vincristine
3
ME-401
3
Doxorubicin
3
umbralisib
2
tazemetostat
2
marizomib
2
epratuzumab
2
Radioimmunodetection
2
voruciclib
1
veltuzumab
1
varlilumab
1
tislelizumab
1
tetulomab tetraxetan lu-177
1
tafasitamab
1
repaglinide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, B-Cell, Marginal Zone
×
Interleukin-2
×
Clear all
NCT05336409
2025-12-18
ELiPSE-1
Century Therapeutics, Inc.
Phase 1
Terminated
28 enrolled